Copper
In clinical developmentAlso known as CI 77400, Cu - copper, Kupfer, Miudella+4 more
CI 77400, Cu - copper, Kupfer, Miudella, ParaGard, cobre, cuivre, cuprum.
Recent clinical, regulatory, research and industry developments relating to this drug.
The molecular mechanism and therapeutic landscape of copper and cuproptosis in cancer.
Cuproptosis: molecular mechanisms, cancer prognosis, and therapeutic applications.
Metabolic cell death in cancer: ferroptosis, cuproptosis, disulfidptosis, and beyond.
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives.
Common and Trace Metals in Alzheimer's and Parkinson's Diseases.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- International journal of molecular sciences3
- Journal of hematology & oncology2
- Signal transduction and targeted therapy2
- Archives of toxicology1
- Autophagy1
- Journal of experimental & clinical cancer research : CR1
- Chen X2
- Liu J2
- Zhang Z2
- Zhao H2
- Alhazza IM1
- Alwasel SH1
- Ayton S1
- Baj J1
- Baylor College of Medicine1
- Beijing Tiantan Hospital1
- Cancer Center1
- Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology1
- Cardinal Stefan Wyszynski University1
- Central Laboratory & Shenzhen Key Laboratory of Epigenetics and Precision Medicine for Cancers1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 3 of the same disease areas as Copper in the shared literature.
Studied across the same disease area as Copper in the shared literature.
Studied across the same disease area as Copper in the shared literature.
Studied across the same disease area as Copper in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials